Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Feb;97(2):262-9.
doi: 10.3324/haematol.2011.050138. Epub 2011 Oct 11.

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma

Luis F Porrata  1 , Kay Ristow, Joseph P Colgan, Thomas M Habermann, Thomas E Witzig, David J Inwards, Stephen M Ansell, Ivana N Micallef, Patrick B Johnston, Grzegorz S Nowakowski, Carrie Thompson, Svetomir N Markovic
Affiliations
Comparative Study

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma

Luis F Porrata et al. Haematologica. 2012 Feb.

Abstract

Background: Lymphopenia and tumor-associated macrophages are negative prognostic factors for survival in classical Hodgkin's lymphoma. We, therefore, studied whether the peripheral blood absolute lymphocyte count/absolute monocyte count ratio at diagnosis affects survival in classical Hodgkin's lymphoma.

Design and methods: We studied 476 consecutive patients with classical Hodgkin's lymphoma followed at the Mayo Clinic from 1974 to 2010. Receiver operating characteristic curves and area under the curve were used to determine cut-off values for the absolute lymphocyte count/absolute monocyte count ratio at diagnosis, while proportional hazards models were used to compare survival based on the absolute lymphocyte count/absolute monocyte count ratio at diagnosis.

Results: The median follow-up period was 5.6 years (range, 0.1-33.7 years). An absolute lymphocyte count/absolute monocyte count ratio at diagnosis of 1.1 or more was the best cut-off value for survival with an area under the curve of 0.91 (95% confidence interval, 0.86 to 0.96), a sensitivity of 90% (95% confidence interval, 85% to 96%) and specificity of 79% (95% confidence interval, 73% to 88%). Absolute lymphocyte count/absolute monocyte count ratio at diagnosis was an independent prognostic factor for overall survival (hazard ratio, 0.18; 95% confidence interval, 0.08 to 0.38, P<0.0001); lymphoma-specific survival (hazard ratio, 0.10; 95% confidence interval, 0.04 to 0.25, P<0.0001); progression-free survival (hazard ratio, 0.35; 95% confidence interval, 0.18 to 0.66, P<0.002) and time to progression (hazard ratio, 0.27; 95% confidence interval, 0.17 to 0.57, P<0.0006).

Conclusions: The ratio of absolute lymphocyte count/absolute monocyte count at diagnosis is an independent prognostic factor for survival and provides a single biomarker to predict clinical outcomes in patients with classical Hodgkin's lymphoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Receiver operating-characteristic curve (ROC) and area under the curve (AUC) for absolute monocyte count at diagnosis (AMC-DX). (B) k-fold cross validation ROC and AUC for AMC-DX. (C) ROC and AUC for absolute lymphocyte count/absolute monocyte count at diagnosis (ALC/AMC-DX). (D) k-fold cross validation ROC and AUC for ALC/AMC-DX.
Figure 2.
Figure 2.
(A) Overall survival for absolute monocyte count at diagnosis (AMC-DX). (B) Lymphoma-specific survival for AMC-DX. (C) Progression-free survival for AMC-DX. (D) Time to progression for AMC-DX. (E) Overall survival for ALC/AMC-DX. (F) Lymphoma-specific survival for ALC/AMC-DX. (G) Progression-free survival for ALC/AMC-DX. (H) Time to progression for ALC/AMC-DX.
See this image and copyright information in PMC

Comment in

References

    1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506–14. - PubMed
    1. Colby TV, Hoppe RT, Warnke RA. Hodgkin’s disease: a clinicopathologic study of 659 cases. Cancer. 1981;49(9):1848–58. - PubMed
    1. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27(1):31–9. - PubMed
    1. Alvaro-Naranjo T, Lejeune M, Salvado-Usach MT, Bosch-Princep R, Reverter-Branchat G, Jaen-Martinez G, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin’s lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma. 2005;46(11):1581–91. - PubMed
    1. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362(10):875–85. - PMC - PubMed

Publication types